Human Papilloma Virus (HPV)

China Human Vaccine Industry Report, 2015-2018

A vaccine is a preventive biological product for human use that prevents and controls the occurrence and prevalence of infectious diseases, so the demand for such products is relatively rigid. Due to suspected deaths stemming from vaccination and some companies' (such as Shenzhen Kangtai, Tiantan Biological and Dalian Hissen) production halts of some products because of their failure to pass new GMP certification, China's human vaccine lot release volume in 2014 declined by 2.4% year on year to 791 million doses.

La confiance des médecins dans la vaccination, point clef pour l'application des recommandations vaccinales

Ces dernières années, un accroissement préoccupant d'opinions défavorables à la vaccination a été constaté dans la population générale en France. Plusieurs controverses ont eu lieu depuis la fin des années 1990 :
  • maladies neurodégénératives et vaccination contre l'hépatite B,
  • remise en cause de la vaccination contre la grippe pandémique A(H1N1)pdm09,
  • plaintes pénales à propos d'événements indésirables attribués à la vaccination contre les papillomavirus,
  • mise en cause de l'aluminium présent dans certains vaccins.

ACIP recommends 9-valent HPV vaccine for routine immunization

A 9-valent HPV vaccine is now recommended by the CDC’s Advisory Committee on Immunization Practices as one of the three HPV vaccines that can be used for routine vaccination.
Gardasil 9 (9vHPV, Merck) was approved by the FDA in December 2014 for use among females aged 9 through 26 years and males aged 9 through 15 years. It contains HPV 6, 11, 16 and 18 virus-like particles, similar to the quadrivalent HPV vaccine, as well as HPV 31, 33, 45, 52 and 58 virus-like particles.

Sanofi, Merck win EMA nod for Gardasil 9

Merck's ($MRK) new-and-improved Gardasil is making headway in Europe with the word late last week that the European Medicines Agency (EMA) has recommended the jab against 9 types of human papillomavirus (HPV) and will send its blessing to the European Commission.

European committee gives positive review to GARDASIL 9 HPV vaccine

The European Committee for Medicinal Products for Human Use (CHMP), a branch of the European Medicines Agency (EMA), recently gave positive reviews of the new HPV vaccine, GARDASIL 9.
The new nine-valent HPV vaccine, developed by Sanofi Pasteur MSD, now has the EMA’s recommendation to be authorized for administration to males and females as young as 9 years old. The vaccine is meant to protect people from cervix, vaginal, vulva and anus cancers, in addition to premalignant lesions, genital warts and other HPV symptoms.

Immunization coverage

Key facts
  • Immunization prevents illness, disability and death from vaccine-preventable diseases including cervical cancer, diphtheria, hepatitis B, measles, mumps, pertussis, pneumonia, polio, rotavirus diarrhoea, rubella and tetanus.
  • Global vaccination coverage is holding steady.
  • Immunization currently averts an estimated 2 to 3 million deaths every year.
  • But an estimated 21.8 million infants worldwide are still missing out on basic vaccines.

Takeda transfers HPV vaccine rights as it continues globalization push

Takeda has been singing a globalization mantra when it comes to its vaccines unit, and that's already led it to dump one R&D program as it zeroes in on "higher impact" public health endeavors. Now, it's bowing out of another vaccine program--this time for HPV.

CDC advisory panel recommends HPV vaccine

The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention (CDC) added GARDASIL 9 to its list of recommended HPV vaccines, the nine-valent HPV vaccine’s maker Merck said on Thursday.
The recommendations call for females between the ages of 9 and 26 and males between the ages of 9 and 21 receive the vaccine.
The CDC committee especially recommends the vaccine for people who have not yet received any HPV vaccine or finished the 3 doses.

Serum Institute gets Genticel's Vaxiclase tech to develop pertussis vaccine

With recent news of clinical trials for its low-cost HPV vaccine, the Serum Institute made waves in the world of Big Pharma. The India-based vaccinemaker--which is also working on other low-cost vaccines, such as a powdered measles vaccine--is now gearing up to challenge the world's leading vaccinemakers in another area: pertussis.

FDA approves latest Gardasil HPV vaccine

The Food and Drug Administration recently approved Gardasil 9, which guards against nine strains of the human papillomavirus (HPV).
Several recent clinical trials indicate that Gardasil 9 is 97 percent effective in preventing people from contracting vaginal, vulvar and cervical cancers.
One of the studies included 13,000 subjects. The most common side effects included pain at the injection site, headaches, redness and swelling. The FDA has approved the vaccine for females ages 9-25 years old and males 9-15 years old.